What drove the increase in net sales for the first quarter of 2009?

Net sales increased by 9% to $24.6 million, primarily due to strong international shipments, particularly to the UK and Brazil, for single cartridges and TASER X26 ECDs. This growth helped offset a decline in domestic sales, attributed to economic pressures on municipal budgets, and a decrease in consumer product sales like the TASER C2.

Why did the company report a net loss in the first quarter of 2009 after profitability in the prior year?

The company reported a net loss of $0.47 million compared to a profit of $1.2 million in the prior year's quarter. This reversal was mainly due to a significant increase in Research and Development expenses, which nearly doubled to $4.2 million, and a 25% rise in Sales, General, and Administrative expenses, including higher stock-based compensation and legal costs. These investments are intended to support new product development and market expansion.

How is the company's liquidity position?

The company maintains a strong liquidity position with $58.3 million in cash and cash equivalents as of March 31, 2009. This is supported by operating cash flows and an available credit line. A significant portion of these cash equivalents are insured by the federal government's Temporary Guarantee Program for Money Market Funds, providing an additional layer of security.

What are the key investments the company is making for future growth?

The company is significantly increasing its investment in Research and Development, with expenses nearly doubling year-over-year, focusing on new product development such as the AXON and EVIDENCE.com platforms. They also plan to invest between $10.0 to $15.0 million in capital expenditures for 2009, including manufacturing automation equipment.

AXON 10-Q Quarterly Report Q1 FY2009 — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-Q filed May 11, 2009. Cited figures are marked; the original filing is the authoritative source.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported its first quarter 2009 financial results, indicating a shift towards international markets and increased investment in research and development.

While net sales saw a 9% increase year-over-year to $24.6 million^a, driven by strong international demand particularly in the UK and Brazil, domestic sales declined due to economic constraints on municipal spending. This international growth helped offset a decrease in consumer product sales (TASER C2) and TASER Cam. The company experienced a net loss of $0.47 million for the quarter, a reversal from the $1.2 million net income in the prior year's quarter, largely due to a significant increase in R&D expenses and SG&A costs.

Despite the quarterly loss, the company maintains a strong liquidity position with $58.3 million^b in cash and cash equivalents. The company is actively investing in future growth, particularly in R&D for new products like AXON and EVIDENCE.com, and plans further capital expenditures in manufacturing automation. Management expresses confidence that current liquidity, operating cash flow, and its credit facility will be sufficient for at least the next 12 months, though market uncertainties are acknowledged.

02—Key points

Key Highlights

Net sales increased 9% to $24.6 million, primarily driven by strong international demand offsetting domestic sales decline.
International sales represented 37% of total net sales, a significant increase from 13% in the prior year's quarter.
The company reported a net loss of $0.47 million for the quarter, compared to a net income of $1.2 million in Q1 2008.
Research and Development expenses nearly doubled year-over-year to $4.2 million, reflecting increased investment in new product development.
Sales, General, and Administrative (SG&A) expenses increased by 25% to $11.5 million, partly due to higher stock-based compensation and legal fees.
Cash and cash equivalents stood strong at $58.3 million, providing robust liquidity.
The company has no outstanding debt and a substantial portion of its cash is insured by the federal government's Temporary Guarantee Program for Money Market Funds.

03—Questions

Frequently Asked Questions

What drove the increase in net sales for the first quarter of 2009?
Net sales increased by 9% to $24.6 million, primarily due to strong international shipments, particularly to the UK and Brazil, for single cartridges and TASER X26 ECDs. This growth helped offset a decline in domestic sales, attributed to economic pressures on municipal budgets, and a decrease in consumer product sales like the TASER C2.
Why did the company report a net loss in the first quarter of 2009 after profitability in the prior year?
The company reported a net loss of $0.47 million compared to a profit of $1.2 million in the prior year's quarter. This reversal was mainly due to a significant increase in Research and Development expenses, which nearly doubled to $4.2 million, and a 25% rise in Sales, General, and Administrative expenses, including higher stock-based compensation and legal costs. These investments are intended to support new product development and market expansion.
How is the company's liquidity position?
The company maintains a strong liquidity position with $58.3 million in cash and cash equivalents as of March 31, 2009. This is supported by operating cash flows and an available credit line. A significant portion of these cash equivalents are insured by the federal government's Temporary Guarantee Program for Money Market Funds, providing an additional layer of security.
What are the key investments the company is making for future growth?
The company is significantly increasing its investment in Research and Development, with expenses nearly doubling year-over-year, focusing on new product development such as the AXON and EVIDENCE.com platforms. They also plan to invest between $10.0 to $15.0 million in capital expenditures for 2009, including manufacturing automation equipment.

04—Continue

← View all 10-Q filings